Wednesday, 31 August 2011
Andover, Mass., USA and Galway, Ireland Royal Philips Electronics (AEX: PHI; NYSE: PHG) and Aerogen, a Galway, Ireland-based medical technology and drug delivery company, have collaborated to develop the NIVO Nebulising System, a new drug delivery system designed for use with patients receiving non-invasive ventilation (NIV). The Aerogen nebuliser, which is intended for use with the Philips Respironics Nebulising elbows and AF531 mask, incorporates Aerogens multi-patented aerosol generator, which is based on vibrating mesh plate technology and enables the delivery of aerosolised medication to the lungs.
NIV allows the patient to be ventilated through a mask, without the need for invasive endotracheal tubing. It is a growth market, in both the intensive care and home care setting. The rise in the market for NIV is connected, in part, to the increase in cases of chronic obstructive pulmonary disorder (COPD), which affects 64 million people globally. The market is reported to grow significantly with the World Health Organisation predicting that COPD will become the third leading cause of death worldwide by 2030.
Identifying the need for aerosolised drugs to be delivered through non-invasive means, Philips and Aerogen worked to design a customised nebulisation solution for use with the Philips Respironics AF531 masks. The NIVO product is the first customised nebuliser enabling targeted drug delivery through an NIV system. Launched this month, the NIVO nebuliser is available through the Philips Healthcare sales network.
Aerogens CEO, John Power is very confident of the success of the Philips collaboration in terms of Aerogens growth stating, Philips has a high standard for delivering solutions for patient care, and our shared commitment to innovation made for a good fit for this collaboration. Our technology adds significant value to mechanical ventilation in terms of high efficient aerosol therapy to patients who need it most, often in life and death situations.
Aerogens nebulisers are recognised as the gold standard for nebulisation in the intensive care setting, which was an important factor in selecting the best partner to help develop this product, said Randall Whitfield, general manager, Hospital Respiratory Care, for Philips Healthcare. With the rise in pulmonary disease, developing a means to deliver drug therapy via non-invasive ventilation is a significant step in helping to improve patient care.